

Volume 57, Supplement 3 • October 2016

- 1S** **Radiotheranostics in Prostate Cancer: Introduction and Overview**
Hossein Jadvar
- 3S** **Molecular Imaging and Targeted Radionuclide Therapy of Prostate Cancer**
Wolfgang A. Weber and Michael J. Morris
- 6S** **What Medical, Urologic, and Radiation Oncologists Want from Molecular Imaging of Prostate Cancer**
Leslie K. Ballas, Andre Luis de Castro Abreu, and David I. Quinn
- 13S** **Utility of Ultrasound in the Diagnosis, Treatment, and Follow-up of Prostate Cancer: State of the Art**
Frank K. Chen, Andre Luis de Castro Abreu, and Suzanne L. Palmer
- 19S** **Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer**
Andrei H. Iagaru, Erik Mittra, Patrick M. Colletti, and Hossein Jadvar
- 25S** **PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer**
Hossein Jadvar
- 30S** **Evaluation of Prostate Cancer with ¹¹C-Acetate PET/CT**
Claudio Spick, Ken Herrmann, and Johannes Czernin
- 38S** **Evaluation of Prostate Cancer with ¹¹C- and ¹⁸F-Choline PET/CT: Diagnosis and Initial Staging**
Sascha Nitsch, Oliver W. Hakenberg, Martin Heuschkel, Desiree Dräger, Guido Hildebrandt, Bernd J. Krause, and Sarah M. Schwarzenböck
- 43S** **¹¹C- or ¹⁸F-Choline PET/CT for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer**
Paola Mapelli, Elena Incerti, Francesco Ceci, Paolo Castellucci, Stefano Fanti, and Maria Picchio
- 49S** **Evaluation of Prostate Cancer with ¹¹C-Choline PET/CT for Treatment Planning, Response Assessment, and Prognosis**
Francesco Ceci, Paolo Castellucci, Paola Mapelli, Elena Incerti, Maria Picchio, and Stefano Fanti
- 55S** **Evaluation of Prostate Cancer Bone Metastases with ¹⁸F-NaF and ¹⁸F-Fluorocholine PET/CT**
Mohsen Beheshti, Alireza Rezaee, Hans Geinitz, Wolfgang Loidl, Christian Pirich, and Werner Langsteiger
- 61S** **Evaluation of Prostate Cancer with Radiolabeled Amino Acid Analogs**
David M. Schuster, Cristina Nanni, and Stefano Fanti
- 67S** **Bombesin-Targeted PET of Prostate Cancer**
Rosalba Mansi, Ryogo Minamimoto, Helmut Mäcke, and Andrei H. Iagaru
- 73S** **Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor–Axis Imaging**
Neeta Pandit-Taskar, Darren R. Veach, Josef J. Fox, Howard I. Scher, Michael J. Morris, and Steven M. Larson
- 79S** **The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer**
Ali Afshar-Oromieh, John W. Babich, Clemens Kratochwil, Frederik L. Giesel, Michael Eisenhut, Klaus Kopka, and Uwe Haberkorn
- 90S** **Prostate-Specific Membrane Antigen–Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer**
Steven P. Rowe, Alexander Drzezga, Bernd Neumaier, Markus Dietlein, Michael A. Gorin, Michael R. Zalutsky, and Martin G. Pomper
- 97S** **PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013**
Harshad R. Kulkarni, Aviral Singh, Christiane Schuchardt, Karin Niepsch, Manal Sayeg, Yevgeniy Leshch, Hans-Juergen Wester, and Richard P. Baum
- 105S** **Prostate Cancer Imaging and Therapy: Potential Role of Nanoparticles**
Aoife Kilcoyne, Mukesh G. Harisinghani, and Umar Mahmood
- 111S** **Evaluation of Prostate Cancer with PET/MRI**
Liza Lindenberg, Mark Ahlman, Baris Turkbey, Esther Mena, and Peter Choyke

EDITORIAL BOARD

Guest Editor

Hossein Jadvar, MD, PhD, MPH, MBA, FACNM, FSNMMI
University of Southern California
Los Angeles, California

Editor-in-Chief

Dominique Delbeke, MD, PhD
Vanderbilt University Medical Center
Nashville, Tennessee

Opinions expressed in the contributions to this supplement are solely those of the authors and do not necessarily reflect those of *The Journal of Nuclear Medicine* or the Society of Nuclear Medicine and Molecular Imaging. The journal, however, invites and welcomes different opinions in order to initiate and stimulate discussion.